Alnylam earnings flagged as poor profitability guide
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Alnylam Pharmaceuticals' recent earnings disappointed on weak underlying factors, with an accrual ratio of 1.33 showing free cash flow is significantly weaker than reported profit. A one-off Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context